Butonitazene, categorized as a benzimidazole-derived substance with opioid properties, has been available on the internet as a designer drug. In its natural form, it exhibits moderate potency when compared to its chemical counterparts. It is commonly found as part of blends containing various substances rather than in its unadulterated state. Nevertheless, it remains significantly more potent than morphine and has been linked to multiple incidents of drug overdoses. In the United States, Butonitazene is classified as a Schedule I controlled substance, a designation shared with various related compounds.

IUPAC name
CAS Number95810-54-1
PubChem CID156588955
Chemical and physical data
Molar mass424.545 g·mol−1


  • What is Butonitazene?
  • Butonitazene is a synthetic opioid that belongs to the benzimidazole class of compounds. It is known for its opioid effects and has been marketed and sold as a designer drug, often via online sources.
  • How is Butonitazene used?
  • Butonitazene is typically consumed by users seeking its opioid effects. It is often ingested orally, but it may also be used in other forms, such as nasal sprays or intravenous injections.
  • Is Butonitazene legal?
  • In many regions, including the United States, Butonitazene is classified as a Schedule I controlled substance. This designation means it is illegal to manufacture, possess, or distribute for any purpose.
  • What are the effects of Butonitazene?
  • The effects of Butonitazene are similar to other opioids and may include pain relief, sedation, and a sense of euphoria. It is essential to note that, like other opioids, Butonitazene carries a significant risk of addiction and overdose.
  • Is Butonitazene safe?
  • Butonitazene is associated with a high risk of overdose and addiction, making it a dangerous substance. Using this drug can lead to severe health complications, including respiratory depression, coma, and death.
  • Are there any risks associated with Butonitazene use?
  • Yes, there are substantial risks. Butonitazene use is associated with a high risk of overdose, especially when users are unaware of its potency. Combining it with other substances, including alcohol, can increase the danger.
  • What are the signs of a Butonitazene overdose?
  • Symptoms of Butonitazene overdose may include extreme drowsiness, slow or shallow breathing, pinpoint pupils, loss of consciousness, and even death. If someone exhibits these signs after using Butonitazene, it’s crucial to seek immediate medical help.
  • Can Butonitazene be detected in drug tests?
  • Yes, Butonitazene can be detected in standard opioid drug tests. Testing methods can identify its presence in urine, blood, or other bodily fluids.
  • Is there any safe use of Butonitazene?
  • No, there is no safe use of Butonitazene. Due to its high risk of addiction and overdose, it is strongly discouraged, and its use is illegal in many countries.
  • Where can I get help for Butonitazene addiction?
    If you or someone you know is struggling with Butonitazene addiction, it is essential to seek professional help immediately. You can contact addiction treatment centers, healthcare providers, or addiction helplines for guidance and support.


  1. Anvisa (2023-03-31): “Resolução da Diretoria Colegiada nº 784 – Listas de Substâncias Entorpecentes, Psicotrópicas, Precursoras e Outras sob Controle Especial” [Collegiate Board Resolution No. 784 – Lists of Narcotic, Psychotropic, Precursor, and Other Substances under Special Control] (in Brazilian Portuguese). Published in Diário Oficial da União on 2023-04-04. Archived from the original on 2023-08-03. Retrieved on 2023-08-15.
  2. Schumann JL, Syrjanen R, Alford K, Mashetty S, Castle JW, Rotella J, et al. (August 2022): “Incidents in an Australian Emergency Department Involving ‘Nitazene’ Benzylbenzimidazole Synthetic Opioids (Etodesnitazene, Butonitazene, and Protonitazene).” Published in the Journal of Analytical Toxicology. Volume 47, Issue 1, pages e6–e9. doi: 10.1093/jat/bkac062. PMID: 35983900.
  3. Montanari E, Madeo G, Pichini S, Busardò FP, Carlier J (August 2022): “Acute Poisonings and Fatalities Associated With Benzimidazole Opioid (Nitazene Analog) Usage: A Comprehensive Review.” Featured in Therapeutic Drug Monitoring. Volume 44, Issue 4, pages 494–510. doi: 10.1097/FTD.0000000000000970. PMID: 35149665. S2CID: 246776288.
  4. Walton SE, Krotulski AJ, Logan BK (March 2022): “A Progressive Strategy for Tackling the Novel Synthetic Opioid 2-Benzylbenzimidazole Nitazene Analogs Using Liquid Chromatography-Tandem Quadrupole Mass Spectrometry (LC-QQQ-MS).” Published in the Journal of Analytical Toxicology. Volume 46, Issue 3, pages 221–231. doi: 10.1093/jat/bkab117. PMC: 8935987. PMID: 34792157.
  5. “21 CFR Part 1308. [Docket No. DEA–900] Schedules of Controlled Substances: Temporary Placement of Butonitazene, Etodesnitazene, Flunitazene, Metodesnitazene, Metonitazene, N-Pyrrolidino etonitazene, and Protonitazene in Schedule I.” (PDF). Published in the Federal Register by the Drug Enforcement Administration. Volume 87, Issue 70, page 21556. Dated 12 April 2022.

Leave a Comment

Your email address will not be published. Required fields are marked *